Please read and agree to the terms and conditions of this site.
@xconomy.com 12 days ago
FDA Rejects Boehringer Ingelheim, Eli Lilly Drug for Type 1 Diabetes
@xconomy.com 1 month ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com 1 month ago
Esperion’s Combo Pill for Lowering Cholesterol Levels Wins FDA Nod
@xconomy.com 1 month ago
UK Reveals Plans For ‘Dynamic’ Post-Brexit Regulatory System
@xconomy.com 1 month ago
UK Reveals Plans For ‘Dynamic’ Post-Brexit Regulatory System
@xconomy.com 1 month ago
UK Reveals Plans For ‘Dynamic’ Post-Brexit Regulatory System
@xconomy.com 1 month ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com 1 month ago
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer
@xconomy.com 1 month ago
CRISPR, CAR-T, Consolidation: Top Advanced Therapy Milestones of 2019
@xconomy.com 2 months ago
Titan Medical’s Cash Crunch Stalls Plans to Get Surgical Robot to FDA
@xconomy.com 2 months ago
Aimmune Awarded First FDA Approval for a Peanut Allergy Therapy
@xconomy.com 2 months ago
Bio Roundup: Mammoth Moves, Black Diamond’s Pop, Ohana’s Debut & More
@xconomy.com 2 months ago
Decibel Therapeutics Strikes a Balance, Adding Regenerative Med Focus
@xconomy.com 2 months ago
Revolution Medicines Maps Out an IPO to Reach Cancer’s Frontiers
@xconomy.com 2 months ago
Schrödinger Sets Course for IPO to Support Growing Internal Pipeline
@xconomy.com 2 months ago
DTx Pharma Raises $10.6M to Advance New Way to Deliver RNA Drugs
@xconomy.com 2 months ago
Black Diamond Lines Up IPO as Lead Cancer Drug Nears Clinic
@xconomy.com 3 months ago
Allergan Wins FDA Nod for First Migraine Pill in New Class of Medicines
@xconomy.com 3 months ago
Amgen’s Osteoporosis Drug Wins European Nod, With a Heart Warning
@xconomy.com 4 months ago
Novartis to Acquire MedCo and FDA-Ready Cholesterol Drug for $9.7B
@xconomy.com 5 months ago
Roche to Pay Dicerna Pharma $200M to Team Up on Hepatitis B Drug
@xconomy.com 5 months ago
Disc Medicine Launches With $50M to Advance New Anemia Treatments
@xconomy.com 5 months ago
FDA OKs Lilly’s Lasmiditan, First New Acute Migraine Drug in Decades
@xconomy.com 5 months ago
UCB Stakes Out Autoimmune Territory With $2.1B Deal for Ra Pharma
@xconomy.com 6 months ago
Biotech Roundup: Vaping Toll Rises, NASH News, Akcea Shakeup & More
@xconomy.com 6 months ago
MedCo Preps for FDA Filing as Cholesterol Drug Clears Last Two Tests
@xconomy.com 6 months ago
Bio Roundup: Award Winners, Lung Data, Dems on Drug Pricing & More
@xconomy.com 6 months ago
SpringWorks and Satsuma Boost This Week’s Biotech IPO Haul to $595M
@xconomy.com 7 months ago
Frequency Plans IPO for Hearing Loss Drug & More Regenerative Meds
@xconomy.com 7 months ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com 7 months ago
As Cholesterol Drug Aces Big Test, MedCo CEO Open to Flexible Pricing
@xconomy.com 7 months ago
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More
@xconomy.com 7 months ago
Pfizer Spinout SpringWorks, Migraine Drug Firm Satsuma Prep IPOs
@xconomy.com 7 months ago
Chasing Blueprint, Deciphera Plans FDA Filing for GI Cancer Drug
@xconomy.com 9 months ago
With Data, Pfizer/Sangamo Step Forward in Hemophilia Gene Therapy Race
@xconomy.com 9 months ago
PanTheryx Lands $50M to Use “First Milk” to Target Gut Microbiome
@xconomy.com 9 months ago
Synlogic Lands $80M from Ginkgo to Ramp Up “Living Medicines” R&D
@xconomy.com 10 months ago
With $35M, Whole Biome Eyes 2020 Launch of Medical Food for Diabetes
@xconomy.com 10 months ago
MedCo Touts New Data for Long-Lasting Heart Drug as Reckoning Looms
@xconomy.com 10 months ago
Bio Roundup: Generic Drugs Graft, ASCO Ahead, ElevateBio Rises & More
@xconomy.com 11 months ago
FDA OKs Pfizer Rare Disease Drug, Sets Up Battle With Alnylam, Akcea
@xconomy.com 11 months ago
Bio Roundup: Head and Spine Previews, Biogen Moves, IPO Dreams & More
@xconomy.com 11 months ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com 11 months ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com 1 year ago
Bio Roundup: Amyloid Angst, NASH News, Brammer Bagged & More
@xconomy.com 1 year ago
New Data Puts Aldeyra One Step Closer to FDA Filing for Eye Drug
@xconomy.com 1 year ago
FDA OKs Depression Drug For New Moms: Fast Relief But Tough to Take
@xconomy.com 1 year ago
Rani’s “Robotic Pill” for Biologics Clears First Hurdle in Humans